“Medivation and Pfizer [the companies developing dimebon] also have unpublished data showing that dimebon increases neurite outgrowth, which is a metabolically demanding process, and healthy mitochondria are essential for that,” Dr. Smith said.
But so far, he said, dimebon's method of action in improving cognition in AD remains unproven. “There are a lot of dots that form the shape of a mitochondria, but no one has connected them all yet.”
Neither Dr. Gandy nor Dr. Smith had any relevant disclosures to make.
'The levels of the amyloid peptides in the interstitial brain fluid roughly doubled whenever the drug was given.'
Source Dr. Gandy